CN119234042A - 具有延长的半衰期的信使核糖核酸 - Google Patents

具有延长的半衰期的信使核糖核酸 Download PDF

Info

Publication number
CN119234042A
CN119234042A CN202380041777.XA CN202380041777A CN119234042A CN 119234042 A CN119234042 A CN 119234042A CN 202380041777 A CN202380041777 A CN 202380041777A CN 119234042 A CN119234042 A CN 119234042A
Authority
CN
China
Prior art keywords
seq
mrna
nucleic acid
utr
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380041777.XA
Other languages
English (en)
Chinese (zh)
Inventor
D·里德
M·A·齐默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
ModernaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ModernaTx Inc filed Critical ModernaTx Inc
Publication of CN119234042A publication Critical patent/CN119234042A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202380041777.XA 2022-03-25 2023-03-24 具有延长的半衰期的信使核糖核酸 Pending CN119234042A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263323748P 2022-03-25 2022-03-25
US63/323748 2022-03-25
US202263405142P 2022-09-09 2022-09-09
US63/405142 2022-09-09
US202263419924P 2022-10-27 2022-10-27
US63/419924 2022-10-27
PCT/US2023/016192 WO2023183550A2 (en) 2022-03-25 2023-03-24 Messenger ribonucleic acids with extended half-life

Publications (1)

Publication Number Publication Date
CN119234042A true CN119234042A (zh) 2024-12-31

Family

ID=86330236

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380041777.XA Pending CN119234042A (zh) 2022-03-25 2023-03-24 具有延长的半衰期的信使核糖核酸

Country Status (6)

Country Link
US (1) US20250313830A1 (enExample)
EP (1) EP4499850A2 (enExample)
JP (1) JP2025510777A (enExample)
CN (1) CN119234042A (enExample)
TW (1) TW202345870A (enExample)
WO (1) WO2023183550A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118542697B (zh) * 2024-05-13 2025-07-08 广州万方健医药有限公司 性生活使用后的避孕套在同时采集和/或检测男性和女性生殖道病原体中的应用
WO2026085234A1 (en) * 2024-10-18 2026-04-23 Modernatx, Inc. 3' untranslated region sequences for extending messenger ribonucleic acids half-life

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
CA3174553A1 (en) * 2020-03-05 2021-09-10 Flagship Pioneering Innovations Vi, Llc Host defense suppressing methods and compositions for modulating a genome
EP4158005A1 (en) * 2020-06-01 2023-04-05 ModernaTX, Inc. Phenylalanine hydroxylase variants and uses thereof
WO2021248008A1 (en) * 2020-06-05 2021-12-09 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections
EP4168556A2 (en) * 2020-06-23 2023-04-26 ModernaTX, Inc. Lnp compositions comprising mrna therapeutics with extended half-life

Also Published As

Publication number Publication date
TW202345870A (zh) 2023-12-01
JP2025510777A (ja) 2025-04-15
US20250313830A1 (en) 2025-10-09
EP4499850A2 (en) 2025-02-05
WO2023183550A3 (en) 2023-11-09
WO2023183550A2 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
ES2992653T3 (en) Methods of preparing lipid nanoparticles
EP3852728B1 (en) Preparation of lipid nanoparticles and methods of administration thereof
JP7065036B2 (ja) メチルマロニルＣｏＡムターゼをコードするポリヌクレオチド
EP4096644A1 (en) Methods of preparing lipid nanoparticles
EP4286012A2 (en) Compounds and compositions for intracellular delivery of therapeutic agents
CN116194151A (zh) 包含具有延长的半衰期的mRNA治疗剂的LNP组合物
US20220251577A1 (en) Endonuclease-resistant messenger rna and uses thereof
JP2023527875A (ja) フェニルアラニンヒドロキシラーゼバリアント及びその使用
CN119234042A (zh) 具有延长的半衰期的信使核糖核酸
US20250213664A1 (en) Mrnas encoding checkpoint cancer vaccines and uses thereof
WO2019200171A1 (en) Messenger rna comprising functional rna elements
CA3158013A1 (en) Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
EP3965806A1 (en) Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
US20240401006A1 (en) Mrnas encoding chimeric metabolic reprogramming polypeptides and uses thereof
CN118946365A (zh) 编码检查点癌症疫苗的mRNA及其用途
JP2024540170A (ja) インテグリンベータ－６をコードするポリヌクレオチド及びその使用方法
HK40078722A (en) Compounds and compositions for intracellular delivery of agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20241231